Interventions of Interest:

  • Tezepelumab (Amgen, AstraZeneca)

The Centers for Disease Control and Prevention (CDC) estimates that 25 million Americans have asthma of whom 5 million are children. Asthma causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Many processes contribute to the narrowing, including tightening of the muscles around the airways, inflamed tissue lining the airways, and mucous plugging of the airways. The disease follows a waxing and waning course with exacerbations initiated by allergens, cold weather, exercise, pollution, and other triggers. This leads to approximately 10 million office visits, 1.6 million emergency room visits, 180,000 hospitalizations, and 3,500 deaths each year in the US.1,2 The societal costs are estimated to be $82 billion including $50 billion in direct medical costs, $29 billion from asthma-related mortality, and $3 billion from missed work and school

For more information, please contact Catherine Koola, Program Manager, at

View the Key Stakeholder List